Two Year Update of Pivotal JAVELIN Merkel 200 Trial Shows Continued Durable Responses with BAVENCIO® (avelumab)
Chicago (ots/PRNewswire) - Not intended for US, Canada and UK-based media - Two-year follow-up data on meaningful durable response, overall survival (OS) and progression-free survival (PFS) to be presented in patients with metastatic Merkel cell carcinoma (mMCC), a rare and aggressive type of skin cancer Merck and ...